Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Reeves

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Plos Pathogens|January 19, 2021
Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ARTCharline Bacchus-Souffan, Mark Fitch, Jori Symons, et al.
Med (New York, N.Y.)|July 23, 2022
Acute HIV-1 infection viremia associate with rebound upon treatment interruptionThembi Mdluli, Yifan Li, Suteeraporn Pinyakorn, et al.
Plos Pathogens|February 7, 2020
Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and ThailandMorgane Rolland, Sodsai Tovanabutra, Bethany Dearlove, et al.
Nature|December 1, 2025
Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantationChristian Gaebler, Samad Kor, Kristina Allers, et al.
Nature Communications|March 23, 2024
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Nature Communications|December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Mbio|September 9, 2025
Bayesian estimation of HIV acquisition dates for prevention trialsRaabya Rossenkhan, Elena E Giorgi, Danica Shao, et al.
Nature Medicine|August 22, 2022
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisitionPeter B Gilbert, Yunda Huang, Allan C deCamp, et al.
Nature Communications|April 3, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Plos Pathogens|January 19, 2021
Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ARTCharline Bacchus-Souffan, Mark Fitch, Jori Symons, et al.
Med (New York, N.Y.)|July 23, 2022
Acute HIV-1 infection viremia associate with rebound upon treatment interruptionThembi Mdluli, Yifan Li, Suteeraporn Pinyakorn, et al.
Plos Pathogens|February 7, 2020
Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and ThailandMorgane Rolland, Sodsai Tovanabutra, Bethany Dearlove, et al.
Nature|December 1, 2025
Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantationChristian Gaebler, Samad Kor, Kristina Allers, et al.
Nature Communications|March 23, 2024
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Nature Communications|December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Mbio|September 9, 2025
Bayesian estimation of HIV acquisition dates for prevention trialsRaabya Rossenkhan, Elena E Giorgi, Danica Shao, et al.
Nature Medicine|August 22, 2022
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisitionPeter B Gilbert, Yunda Huang, Allan C deCamp, et al.
Nature Communications|April 3, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Pageof 7